» Authors » Paul Karpecki

Paul Karpecki

Explore the profile of Paul Karpecki including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 33
Citations 930
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Gupta P, Karpecki P
Cornea . 2024 Oct; 44(1):128-135. PMID: 39383472
The clinical value of upper eyelid meibographic imaging remains relatively underexplored; consequently, it is not commonly used in clinical assessments. However, its significance could be particularly important for the early...
2.
Davey P, Farid M, Karpecki P, Gaddie I, Chan A, Mun J, et al.
Healthcare (Basel) . 2024 Aug; 12(15). PMID: 39120190
blepharitis, a chronic lid margin disease, is caused by an infestation of mites, the most common ectoparasites in human skin and eyelids. Lotilaner ophthalmic solution, 0.25% (Xdemvy, Tarsus Pharmaceuticals), is...
3.
Wirta D, Lipsky W, Toyos M, Martel J, Goosey J, Verachtert A, et al.
BMC Ophthalmol . 2024 Jul; 24(1):290. PMID: 39020305
Background: Dry eye disease (DED) includes neurosensory abnormalities as part of its multifactorial etiology. Nerve growth factor is important for maintaining corneal nerve integrity and wound healing. Cenegermin (recombinant human...
4.
Barnett M, Simmons B, Vollmer P, Patel A, Whitson W, Berdy G, et al.
Optom Vis Sci . 2024 Mar; 101(3):151-156. PMID: 38546756
Significance: Patients with Demodex blepharitis have a considerable symptomatic burden that negatively impacts their daily activities and well-being. Despite chronic manifestations of and problems associated with blepharitis that resulted in...
5.
Holland E, Karpecki P, Fingeret M, Schaeffer J, Gupta P, Fram N, et al.
Clin Ther . 2024 Jan; 46(2):104-113. PMID: 38216351
Purpose: This study was undertaken to evaluate the safety and efficacy of CSF-1 (0.4% pilocarpine hydrochloride ophthalmic solution) for use in individuals with presbyopia. Methods: Two Phase 3 multicenter, randomized,...
6.
Karpecki P, Barghout V, Schenkel B, Huynh L, Khanal A, Mitchell B, et al.
BMC Ophthalmol . 2023 Nov; 23(1):443. PMID: 37919692
Background: Dry eye disease (DED) is a disorder characterized by loss of tear film homeostasis that causes ocular surface inflammation and damage. The incidence of DED increases with age. Cyclosporine...
7.
Gaddie I, Donnenfeld E, Karpecki P, Vollmer P, Berdy G, Peterson J, et al.
Ophthalmology . 2023 Jun; 130(10):1015-1023. PMID: 37285925
Purpose: To evaluate the safety and efficacy of lotilaner ophthalmic solution 0.25% compared with vehicle for the treatment of Demodex blepharitis. Design: Prospective, randomized, double-masked, vehicle-controlled, multicenter, phase 3 clinical...
8.
Rhee M, Yeu E, Barnett M, Rapuano C, Dhaliwal D, Nichols K, et al.
Eye Contact Lens . 2023 Jun; 49(8):311-318. PMID: 37272680
Demodex blepharitis is a common disease of the eyelid, affecting approximately 25 million Americans. This article reviews what is known about the mechanisms and impact of Demodex blepharitis, risk factors,...
9.
Yeu E, Wirta D, Karpecki P, Baba S, Holdbrook M
Cornea . 2022 Aug; 42(4):435-443. PMID: 35965392
Purpose: The purpose of this study was to evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25%, compared with vehicle for the treatment of Demodex blepharitis. Methods: In this...
10.
Shen Lee B, Toyos M, Karpecki P, Schiffbauer J, Sheppard J
Ophthalmol Ther . 2022 May; 11(4):1333-1369. PMID: 35608780
Keratoconjunctivitis sicca, also known as dry eye disease (DED), is a prevalent, multifactorial disease associated with compromised ocular lubrication, ocular surface inflammation and damage, and ocular symptoms. Several anti-inflammatory, topical...